AZ-ASU-PREP-DIGITAL
13.7.2022 13:02:07 CEST | Business Wire | Press release
ASU Prep Digital, an accredited online K-12 school offered through Arizona State University, has partnered with Google Public Sector, to make remote immersive learning technology more accessible to students across the United States and around the world. ASU Prep Learning Cloud is a streaming solution that empowers schools to deliver innovative and interactive 3D learning experiences to students using low-bandwidth devices. The technology was developed on and is powered by Google Cloud.
This new platform invites students to solve challenges by immersing themselves in interactive settings made possible by technology. For example, students can watch geologic formations emerge through simulations rather than reading about it in a textbook. Students can also explore human organs in 3D or examine a plastic mannequin. This brings topics like erosion, hydrolysis, and human anatomy to life.
To successfully complete a lesson, students must think critically about the concept, explore it, and learn through discovery. Real-time, instructive feedback also helps contribute to a more individualized learning experience.
“We’re turning students into explorers by embedding learning into the digital formats that students love,” said David Sudarma, ASU Prep’s chief technology officer. “We spark curiosity by asking students to navigate 3D worlds, hypothesize, and discover knowledge by manipulating game-like simulations to solve real-world problems.”
Advancing Accessibility
The ASU Prep Learning Cloud represents an important step toward accessibility for students in rural areas, with limited broadband access, and districts where limited technology funding makes it difficult to deliver cutting-edge learning opportunities. This immersive cloud-based education technology can be experienced from mobile devices or Chromebooks, increasing accessibility for all learners, anytime, anywhere. Removing those barriers is especially important for a program like ASU Digital Prep, which can be instrumental in bridging gaps for districts where resources are slim.
“ASU Prep Digital has allowed us to partner and advance educational opportunities for thousands of K-12 students who might not have otherwise had access to the courses, credits, mentors, and teachers we offer,” said Arizona State University President Michael Crow, who is widely known as a pioneer of online education.
Crow’s vision has created a tech-enhanced learning environment across ASU, inclusive of pre-collegiate students via ASU Prep Digital. A key element of that vision is expanded opportunities in online education, which offers a path to higher education for students who are otherwise hindered from pursuing their education goals. In addition to its rapidly expanding K-12 enrollment, ASU Prep Digital’s School Partnerships continue to grow. The program supports entire school districts in states like Utah, Louisiana and Ohio, as well as schools in 22 states and 12 countries.
Powerhouse Partnerships
In addition to the full- and part-time students who enroll directly with ASU Prep Digital, the school also teams with private schools, public schools, and districts worldwide to offer a K-12 curriculum and one-on-one instruction in a virtual environment. The program’s latest suite of courses, which will be available this fall to partner schools via the ASU Prep Learning Cloud, powered by Google Cloud, can be used in compliance with Family Educational Rights and Privacy Act (FERPA).
As pioneers in their respective industries, ASU Prep Digital and Google Public Sector worked to develop the platform, which is based on game engine technology. The ASU Prep Learning Cloud features responsive design optimized for the most commonly used devices (e.g., Chromebooks, mobile phones) using Web Content Accessibility Guidelines (WCAG).
“Our partnership with ASU Prep Digital has the ability to unlock new and innovative academic opportunities for learners across the country,” said Steven Butschi, director of Education, Google Public Sector. “We’re unleashing the power of Google Cloud to help make individualized, digital, and interactive learning the new standard in education.”
Courses integrate seamlessly into existing learning management systems, while supporting robust interactive features that personalize learning. The platform currently supports ASU Prep Digital partner schools, but in the future, could be rolled out to other educational institutions.
“As immersive technologies become more widely adapted in education, 3D learning environments such as augmented reality and virtual reality offer great potential for engagement and retention,” Sudarma said. “Our collaboration with Google Public Sector is a terrific first step in expanding access to immersive solutions across many devices, and we’re working together to explore ways immersive technologies can be made even more universally available to eager learners.”
To preview a snapshot of ASU Prep Learning Cloud courses, visit: https://vimeo.com/623494408 or take a deeper look at the immersive platform here: https://vimeo.com/689344144/795e785a7c
About ASU Prep Digital
ASU Prep Digital is an accredited online K-12 school that offers a single online course or enrollment in a full-time, diploma-granting program. Because it is part of Arizona State University, ASU Prep Digital offers an accelerated path toward college admission and the chance to earn concurrent high school and university credit. For more information, visit asuprepdigital.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005336/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
